{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:53:57Z","timestamp":1775210037448,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since enzyme replacement therapy for Gaucher disease (MIM#230800) has become available, both awareness of and the natural history of the disease have changed. However, there remain unmet needs such as the identification of patients at risk of developing bone crisis during therapy and late complications such as cancer or parkinsonism. The Spanish Gaucher Disease Registry has worked since 1993 to compile demographic, clinical, genetic, analytical, imaging and follow-up data from more than 400 patients. The aims of this study were to discover correlations between patients\u2019 characteristics at diagnosis and to identify risk features for the development of late complications; for this a machine learning approach involving correlation networks and decision trees analyses was applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 358 patients, 340 type 1 Gaucher disease and 18 type 3 cases were selected. 18% were splenectomyzed and 39% had advanced bone disease. 81% of cases carried heterozygous genotype. 47% of them were diagnosed before the year 2000. Mean age at diagnosis and therapy were 28 and 31.5\u2009years old (y.o.) respectively. 4% developed monoclonal gammopathy undetermined significance or Parkinson Disease, 6% cancer, and 10% died before this study. Previous splenectomy correlates with the development of skeletal complications and severe bone disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005); serum levels of IgA, delayed age at start therapy (&gt;\u20099.5 y.o. since diagnosis) also correlates with severe bone disease at diagnosis and with the incidence of bone crisis during therapy. High IgG (&gt;\u20091750\u2009mg\/dL) levels and age over 60 y.o. at diagnosis were found to be related with the development of cancer. When modelling the decision tree, patients with a delayed diagnosis and therapy were the most severe and with higher risk of complications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our work confirms previous observations, highlights the importance of early diagnosis and therapy and identifies new risk features such as high IgA and IgG levels for long-term complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01520-7","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T04:02:39Z","timestamp":1600747359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Identification of risk features for complication in Gaucher\u2019s disease patients: a machine learning analysis of the Spanish registry of Gaucher disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Marcio M.","family":"Andrade-Campos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura L\u00f3pez","family":"de Frutos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge J.","family":"Cebolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Serrano-Gonzalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Medrano-Engay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Roca-Espiau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Gomez-Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"P\u00e9rez-Heredia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Iniguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-1901","authenticated-orcid":false,"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"1520_CR1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0950-3536(97)80031-5","volume":"10","author":"RO Brady","year":"1997","unstructured":"Brady RO. Gaucher\u2019s disease: past, present and future. Bailleres Clin Haematol. 1997;10:621\u201334.","journal-title":"Bailleres Clin Haematol"},{"key":"1520_CR2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0950-3536(97)80033-9","volume":"10","author":"TM Cox","year":"1997","unstructured":"Cox TM, Schofield JP. Gaucher\u2019s disease: clinical features and natural history. Baillieres Clin Haematol. 1997;10:657\u201389.","journal-title":"Baillieres Clin Haematol"},{"key":"1520_CR3","unstructured":"Orphanet \/ INSERM US14. Orphanet Web Site. [Online]. Available from: https:\/\/www.orpha.net. Accessed 10 May 2020."},{"key":"1520_CR4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1023\/A:1008878425167","volume":"7","author":"RP Hayes","year":"1998","unstructured":"Hayes RP, Grinzaid KA, Duffey EB, Elsas LJ 2nd. The impact of Gaucher disease and its treatment on quality of life. Qual Life Res. 1998;7:521\u201334.","journal-title":"Qual Life Res"},{"key":"1520_CR5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","volume":"14","author":"P Giraldo","year":"2005","unstructured":"Giraldo P, Solano V, P\u00e9rez-Calvo JI, Giralt M, Rubio-F\u00e9lix D. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res. 2005;14:453\u201362.","journal-title":"Qual Life Res"},{"key":"1520_CR6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","volume":"18","author":"BE Rosenbloom","year":"2013","unstructured":"Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncog. 2013;18:163\u201375.","journal-title":"Crit Rev Oncog"},{"key":"1520_CR7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.","journal-title":"Int J Mol Sci"},{"key":"1520_CR8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0950-3536(97)80032-7","volume":"10","author":"GA Grabowski","year":"1997","unstructured":"Grabowski GA, Horowitz M. Gaucher\u2019s disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol. 1997;10:635\u201356.","journal-title":"Baillieres Clin Haematol."},{"key":"1520_CR9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10038-007-0135-4","volume":"52","author":"P Alfonso","year":"2007","unstructured":"Alfonso P, Aznarez S, Giralt M, Pocovi M, Giraldo P. Mutation analysis and genotype\/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet. 2007;52:391\u20136.","journal-title":"J Hum Genet"},{"issue":"Suppl 1","key":"1520_CR10","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1002\/ajh.24063","volume":"90","author":"GA Grabowski","year":"2015","unstructured":"Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher registry. Am J Hematol. 2015;90(Suppl 1):S12\u20138.","journal-title":"Am J Hematol"},{"issue":"2","key":"1520_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.24957","volume":"93","author":"A Zimran","year":"2018","unstructured":"Zimran A, Belmatoug N, Bembi B, Deegan P, Elstein D, Fernandez-Sasso D, Giraldo P, Goker-Alpan O, Lau H, Lukina E, Panahloo Z, Schwartz IVD, GOS Study group. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher outcome survey (GOS). Am J Hematol. 2018;93(2):205\u201312.","journal-title":"Am J Hematol"},{"key":"1520_CR12","first-page":"792","volume":"85","author":"P Giraldo","year":"2000","unstructured":"Giraldo P, Pocov\u00ed M, P\u00e9rez-Calvo J, Rubio-F\u00e9lix D, Giralt M. Report of the Spanish Gaucher\u2019s disease registry: clinical and genetic characteristics. Haematologica. 2000;85:792\u20139.","journal-title":"Haematologica"},{"key":"1520_CR13","first-page":"213","volume":"7B","author":"K Fried","year":"1958","unstructured":"Fried K. Gaucher\u2019s disease among the Jews of Israel. Bull Res Council Isr. 1958;7B:213.","journal-title":"Bull Res Council Isr"},{"key":"1520_CR14","first-page":"303","volume":"61","author":"PO Hillborg","year":"1959","unstructured":"Hillborg PO. Morbus Gaucher: Norbotten. Nord Med. 1959;61:303.","journal-title":"Nord Med"},{"key":"1520_CR15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0888-7543(89)90319-4","volume":"4","author":"M Horowitz","year":"1989","unstructured":"Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, Beutler E. The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics. 1989;4:87\u201396.","journal-title":"Genomics"},{"key":"1520_CR16","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372:1263\u201371.","journal-title":"Lancet."},{"key":"1520_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","volume":"7","author":"J Stirnemann","year":"2012","unstructured":"Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, Rose C, Camou F, de Roux-Serratrice C, Grosbois B, Kaminsky P, Robert A, Caillaud C, Froissart R, Levade T, Masseau A, Mignot C, Sedel F, et al. The French Gaucher\u2019s disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis. 2012;7:77.","journal-title":"Orphanet J Rare Dis"},{"key":"1520_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1172-7-17","volume":"7","author":"P Giraldo","year":"2012","unstructured":"Giraldo P, Alfonso P, Ir\u00fan P, Gort L, Chab\u00e1s A, Vilageliu L, Grinberg D, S\u00e1 Miranda CM, Pocovi M. Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula. Orphanet J Rare Dis. 2012;7:17.","journal-title":"Orphanet J Rare Dis"},{"key":"1520_CR19","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991;324:1464\u201370.","journal-title":"N Engl J Med"},{"key":"1520_CR20","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1073\/pnas.74.10.4620","volume":"74","author":"E Beutler","year":"1977","unstructured":"Beutler E, Dale GL, Guinto DE, Kuhl W. Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. Proc Natl Acad Sci U S A. 1977;74:4620\u20133.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1520_CR21","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","volume":"115","author":"A Zimran","year":"2010","unstructured":"Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, Wang N, Bhirangi K, Cohn GM, Elstein D. Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010;115:4651\u20136.","journal-title":"Blood."},{"key":"1520_CR22","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Mu\u00f1oz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118:5767\u201373.","journal-title":"Blood."},{"key":"1520_CR23","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hreb\u00edcek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A. Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355:1481\u20135.","journal-title":"Lancet"},{"key":"1520_CR24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116:893.","journal-title":"Blood"},{"key":"1520_CR25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bcmd.2019.04.003","volume":"77","author":"PK Mistry","year":"2019","unstructured":"Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Danda S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Freisens S, Gaemers S, Hadjiev E, Kishnani PS, Lukina E, Maison-Blanche P, Martins AM, Pastores G, Petakov M, et al. Addendum to letter to the editor: safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis. 2019;77:101\u20132.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"1520_CR26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2047-2501-2-3","volume":"2","author":"W Raghupathi","year":"2014","unstructured":"Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Heal Inf Sci Syst. 2014;2(1):3.","journal-title":"Heal Inf Sci Syst"},{"key":"1520_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijinfomgt.2014.10.007","volume":"35","author":"A Gandomi","year":"2015","unstructured":"Gandomi A, Haider M. Beyond the hype: big data concepts, methods, and analytics. Int J Inf Manag. 2015;35:137\u201344.","journal-title":"Int J Inf Manag"},{"key":"1520_CR28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.11648\/j.ajtab.20180402.14","volume":"4","author":"BK Rai","year":"2018","unstructured":"Rai BK, Meshram AA, Gunasekaran A. Big data in healthcare management: a review of literature. Am J Theor Appl Bus. 2018;4:57\u201369.","journal-title":"Am J Theor Appl Bus"},{"key":"1520_CR29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymeth.2019.04.008","volume":"166","author":"L Yu","year":"2019","unstructured":"Yu L, Chao H, Lizhong D, Zhonxia L, Yijie P, Xin G. Deep learning in bioinformatics: introduction, application, and perspective in the big data era. Methods. 2019;166:4\u201321.","journal-title":"Methods."},{"key":"1520_CR30","volume-title":"In pattern recognition and machine learning","author":"CM Bishop","year":"2006","unstructured":"Bishop CM. In pattern recognition and machine learning. New York: Springer-Verlag; 2006."},{"key":"1520_CR31","first-page":"1137","volume":"14","author":"R Kohavi","year":"1995","unstructured":"Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. IJCAI. 1995;14:1137\u201345.","journal-title":"IJCAI"},{"key":"1520_CR32","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2018","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018. Available from https:\/\/www.R-project.org\/."},{"key":"1520_CR33","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"In ggplot2: elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H. In ggplot2: elegant graphics for data analysis. New York: Springer-Verlag; 2016."},{"key":"1520_CR34","volume-title":"rpart: Recursive Partitioning and Regression Trees. R package version 4.1\u201315","author":"T Therneau","year":"2019","unstructured":"Terry Therneau and Beth Atkinson. rpart: Recursive Partitioning and Regression Trees. R package version 4.1\u201315. 2019. Available from https:\/\/CRAN.R-project.org\/package=rpart."},{"issue":"7","key":"1520_CR35","doi-asserted-by":"crossref","first-page":"e0219302","DOI":"10.1371\/journal.pone.0219302","volume":"14","author":"JM Kwon","year":"2019","unstructured":"Kwon JM, Kim KH, Jeon KH, Lee SE, Lee HY, Cho HJ, Choi JO, Jeon ES, Kim MS, Kim JJ, Hwang KK, Chae SC, Baek SH, Kang SM, Choi DJ, Yoo BS, Kim KH, Park HY, Cho MC, Oh BH. Artificial intelligence algorithm for predicting mortality of patients with acute heart failure. PLoS One. 2019;14(7):e0219302.","journal-title":"PLoS One"},{"key":"1520_CR36","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3389\/fphar.2019.01018","volume":"10","author":"Y Fu","year":"2019","unstructured":"Fu Y, Jia J, Yue L, Yang R, Guo Y, Ni X, Shi T. Systematically Analyzing the Pathogenic Variations for Acute Intermittent Porphyria. Front Pharmacol. 2019;10:1018.","journal-title":"Front Pharmacol"},{"key":"1520_CR37","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.kint.2019.11.037","volume":"97","author":"N Garcelon","year":"2020","unstructured":"Garcelon N, Burgun A, Salomon R, Neuraz A. Electronic health records for the diagnosis of rare diseases. Kidney Int. 2020;97:676.","journal-title":"Kidney Int"},{"issue":"12","key":"1520_CR38","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/genes10120978","volume":"10","author":"S Brasil","year":"2019","unstructured":"Brasil S, Pascoal C, Francisco R, Dos Reis FV, Videira PA, Valad\u00e3o AG. Artificial Intelligence (AI) in rare diseases: is the future brighter? Genes (Basel). 2019;10(12):978.","journal-title":"Genes (Basel)"},{"issue":"Suppl 1","key":"1520_CR39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12938-017-0359-2","volume":"16","author":"N Rappaport","year":"2017","unstructured":"Rappaport N, Fishilevich S, Nudel R, Twik M, Belinky F, Plaschkes I, Stein TI, Cohen D, Oz-Levi D, Safran M, Lancet D. Rational confederation of genes and diseases: NGS interpretation via GeneCards, MalaCards and VarElect. Biomed Eng Online. 2017;16(Suppl 1):72.","journal-title":"Biomed Eng Online"},{"issue":"1","key":"1520_CR40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-017-0627-z","volume":"12","author":"M Andrade-Campos","year":"2017","unstructured":"Andrade-Campos M, Alfonso P, Irun P, Armstrong J, Calvo C, Dalmau J, Domingo MR, Barbera JL, Cano H, Fernandez-Gal\u00e1n MA, Franco R, Gracia I, Gracia-Antequera M, Iba\u00f1ez A, Lendinez F, Madruga M, Martin-Hern\u00e1ndez E, O'Callaghan MDM, Del Soto AP, Del Prado YR, Sancho-Val I, Sanjurjo P, Pocovi M, Giraldo P. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease. Orphanet J Rare Dis. 2017;12(1):84.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1520_CR41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00223-014-9923-y","volume":"95","author":"G Marcucci","year":"2014","unstructured":"Marcucci G, Zimran A, Bembi B, Kanis J, Reginster JY, Rizzoli R, Cooper C, Brandi ML. Gaucher disease and bone manifestations. Calcif Tissue Int. 2014;95(6):477\u201394.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"1520_CR42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bcmd.2014.05.005","volume":"53","author":"L van Dussen","year":"2014","unstructured":"van Dussen L, Lips P, van Essen HW, Hollak CE, Bravenboer N. Heterogeneous pattern of bone disease in adult type 1 Gaucher disease: clinical and pathological correlates. Blood Cells Mol Dis. 2014;53(3):118\u201323.","journal-title":"Blood Cells Mol Dis"},{"key":"1520_CR43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.biochi.2015.11.009","volume":"125","author":"L Astudillo","year":"2016","unstructured":"Astudillo L, Therville N, Colacios C, S\u00e9gui B, Andrieu-Abadie N, Levade T. Glucosylceramidases and malignancies in mammals. Biochimie. 2016;125:267\u201380.","journal-title":"Biochimie"},{"issue":"13","key":"1520_CR44","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/ijms20133304","volume":"20","author":"R Indellicato","year":"2019","unstructured":"Indellicato R, Trinchera M. The link between Gaucher disease and Parkinson\u2019s disease sheds light on old and novel disorders of sphingolipid metabolism. Int J Mol Sci. 2019;20(13):3304.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1520_CR45","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","volume":"34","author":"D Hughes","year":"2019","unstructured":"Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, Kindmark A, Mistry P, Poll L, Weinreb N, Deegan P. Gaucher disease in bone: from pathophysiology to practice. J Bone Miner Res. 2019;34(6):996\u20131013.","journal-title":"J Bone Miner Res"},{"key":"1520_CR46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcmd.2016.10.004","volume":"68","author":"M Andrade-Campos","year":"2018","unstructured":"Andrade-Campos M, Valero E, Roca M, Giraldo P, Spanish group on Gaucher Disease. The utility of magnetic resonance imaging for bone involvement in Gaucher disease. Assessing more than bone crises. Blood Cells Mol Dis. 2018;68:126\u201334.","journal-title":"Blood Cells Mol Dis"},{"issue":"9","key":"1520_CR47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.24801","volume":"92","author":"PK Mistry","year":"2017","unstructured":"Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase\/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher registry. Am J Hematol. 2017;92(9):929\u201339.","journal-title":"Am J Hematol"},{"issue":"5","key":"1520_CR48","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29(5):567\u201383.","journal-title":"Hum Mutat"},{"issue":"5","key":"1520_CR49","doi-asserted-by":"crossref","first-page":"e0126153","DOI":"10.1371\/journal.pone.0126153","volume":"10","author":"J Gervas-Arruga","year":"2015","unstructured":"Gervas-Arruga J, Cebolla JJ, de Blas I, Roca M, Pocovi M, Giraldo P. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease. PLoS One. 2015;10(5):e0126153 Published 2015 May 15.","journal-title":"PLoS One"},{"key":"1520_CR50","unstructured":"Raskovalova T, Deegan PB, Mistry PK, Pavlova E, Yang R, Zimran A, Berger J, Bourgne C, Pereira B, Labar\u00e8re J, Berger MG. Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data. Haematologica. 2020."},{"key":"1520_CR51","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1515\/cclm-2019-0949","volume":"58","author":"P Ir\u00fan","year":"2020","unstructured":"Ir\u00fan P, Cebolla JJ, L\u00f3pez de Frutos L, De Castro-Or\u00f3s I, Roca-Espiau M, Giraldo P. LC MS\/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population. Clin Chem Lab Med. 2020;58:798\u2013809.","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"1520_CR52","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.exger.2006.09.005","volume":"41","author":"G Pawelec","year":"2006","unstructured":"Pawelec G. Immunity and ageing in man. Exp Gerontol. 2006;41(12):1239\u201342.","journal-title":"Exp Gerontol"},{"key":"1520_CR53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00277-008-0441-8","volume":"87","author":"M de Fost","year":"2008","unstructured":"de Fost M, Out TA, de Wilde FA, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol. 2008;87:439\u201349.","journal-title":"Ann Hematol"},{"key":"1520_CR54","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/ijms21041247","volume":"21","author":"Y Nguyen","year":"2020","unstructured":"Nguyen Y, Stirnemann J, Lautredoux F, Cador B, Bengherbia M, Yousfi K, Hamroun D, Astudillo L, Billette de Villemeur T, Brassier A, Camou F, Dalbies F, Dobbelaere D, Gaches F, Leguy-Seguin V, Masseau A, Pers YM, Pichard S, Serratrice C, Berger MG, Fantin B, Belmatoug N, on behalf of the French Evaluation of Gaucher Disease. Treatment Committee \u2020 Immunoglobulin Abnormalities in Gaucher disease: an analysis of 278 patients included in the French Gaucher Disease Registry. Int J Mol Sci. 2020;21:1247. https:\/\/doi.org\/10.3390\/ijms21041247.","journal-title":"Int J Mol Sci"},{"key":"1520_CR55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","volume":"374","author":"S Nair","year":"2016","unstructured":"Nair S, Branagan AR, Liu J, Boddupalli CS, Mistry PK, Dhodapkar MV. Clonal immunoglobulin against Lysolipids in the origin of myeloma. N Engl J Med. 2016;374:555\u201361.","journal-title":"N Engl J Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01520-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01520-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01520-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T19:46:28Z","timestamp":1632253588000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01520-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1520"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01520-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-41735\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-41735\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,22]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the patients included in the SRDG have signed an informed consent to the use of their data on research purpose. The scientific and ethics committees of the FEETEG foundation approved this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PhD Jorge J Cebolla is employee of Takeda Pharmaceutical outside the submitted work; all other authors have indicated they have no financial relationships, relevant to this article, to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}